Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that management will participate in two upcoming virtual investor conferences:
- A fireside chat at Stifel’s 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 4 p.m. ET / 1 p.m. PT; and
- A pre-recorded fireside chat at Piper Sandler’s 33rd Annual Healthcare Conference will be available on the conference website beginning at 10 a.m. ET / 7 a.m. PT on November 22, 2021. A link to the fireside chat will also become available at the same time on the Harpoon website on the Events page. Harpoon will be participating in 1x1 meetings with investors on Tuesday, November 30, and meetings can be requested exclusively via Piper Sandler.
The webcasts will be available from the Events and Presentations section of the company’s website at https://ir.harpoontx.com/events-and-presentations and will be archived there shortly after the events.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. The company’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Harpoon Therapeutics, Inc.
Chief Financial Officer
Robert H. Uhl